The systemic treatment of uterine leiomyosarcomas
Authors:
- Anastasios KyriazoglouAKAnastasios Kyriazoglou
- Michalis LiontosMLMichalis Liontos
- Ioannis Ntanasis-StathopoulosINIoannis Ntanasis-Stathopoulos
- Maria GavriatopoulouMGMaria Gavriatopoulou
Open Access
- 2 April 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (13) , e25309
Abstract
Background: Uterine leiomyosarcomas are rare malignant mesenchymal tumors. The systemic treatment of these tumors includes chemotherapy and radiotherapy. However, there are still a lot of unanswered questions regarding the ideal therapeutic approach. Methods: We have conducted a systematic review of the treatment strategies of uterine leiomyosarcomas for the last ten years. Results: Adjuvant chemotherapy is still a matter of dilemma. Doxorubicin based chemotherapy or the combination of Gemcitabine-Docetaxel are the regimens of choice for the first line setting. Beyond the first line, there are several options;, including chemotherapy, targeted therapy, and recently efforts of introducing immunotherapy to the therapeutic armamentarium of clinicians treating uterine leiomyosarcomas. Conclusions: Despite the efforts of the clinicians dealing with uterine leiomyosarcomas, the optimal therapeutic algorithm is yet to be described.Keywords
This publication has 108 references indexed in Scilit:
- Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice GuidelineCurrent Oncology, 2013
- Uterine Leiomyosarcoma Management, Outcome, and Associated Molecular Biomarkers: A Single Institution’s ExperienceAnnals of Surgical Oncology, 2013
- Nationwide Surveillance in Uterine Cancer: Survival Analysis and the Importance of Birth Cohort: 30-Year Population-Based Registry in TaiwanPLOS ONE, 2012
- Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)The Oncologist, 2012
- A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaGynecologic Oncology, 2012
- Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centersGynecologic Oncology, 2011
- An Increasing Role for Trabectedin in Gynecological CancersInternational Journal of Gynecological Cancer, 2011
- Radiothérapie postopératoire dans les sarcomes utérins : étude rétrospective multicentriqueCancer/Radiothérapie, 2011
- A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomasCancer, 2011
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008